Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.235 +0.025 (+2.07%)

Streaming Delayed Price Updated: 12:20 PM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022

March 24, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss

March 21, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 23, 2022

On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Lineage Cell Therapeutics's Return On Capital Employed Insights ↗

March 14, 2022

Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last...

Via Benzinga

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

March 14, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics: Q4 Earnings Insights ↗

March 10, 2022

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement....

Via Benzinga

Lineage Cell Therapeutics's Earnings: A Preview ↗

March 09, 2022

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

January 24, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

January 04, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026

December 21, 2021

Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...

Via FinancialNewsMedia

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗

December 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 20, 2021

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

Via InvestorPlace

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

December 20, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

November 10, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

November 30, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021

November 03, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

November 15, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy ↗

October 21, 2021

Photo by Daniil Kuželev on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

October 26, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗

October 01, 2021

Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting...

Via Benzinga

Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021

October 18, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021

September 20, 2021

From Lineage Cell Therapeutics

Via Business Wire

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

September 30, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

38 Stocks Moving In Wednesday's Mid-Day Session ↗

September 15, 2021

Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of...

Via Benzinga

Topics Intellectual Property

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

53 Biggest Movers From Yesterday ↗

September 16, 2021

Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.